Proof of concept for claudin-targeted drug development
Article first published online: 25 JUN 2012
© 2012 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1258, Barriers and Channels Formed by Tight Junction Proteins II pages 65–70, July 2012
How to Cite
Suzuki, H., Kondoh, M., Takahashi, A. and Yagi, K. (2012), Proof of concept for claudin-targeted drug development. Annals of the New York Academy of Sciences, 1258: 65–70. doi: 10.1111/j.1749-6632.2012.06503.x
- Issue published online: 25 JUN 2012
- Article first published online: 25 JUN 2012
- Clostridium perfringens enterotoxin;
- mucosal absorption;
Claudins (CLs) are a family of tetra-integral membrane proteins that are a key structural and functional component of tight junctions. CLs are overexpressed in some malignant tumors. Claudin-4 is highly expressed in the epithelial cells covering mucosal immune tissues. CLs may therefore be a potential target for improving drug absorption, treating cancer, and developing mucosal vaccine. Research using Clostridium perfringens enterotoxin has resulted in proofs of concept for CL-targeted drug development. A platform for the creation of CL binders, such as immunization of CL and preparation of CL proteins, is now beginning to be established.